Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?

Nephrology Dialysis Transplantation

Volumn 19, Issue SUPPL. 5, 2004, Pages

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Anti inflammatory cytokine therapy; Cytokines; Erythropoietin resistance; Pentoxifylline

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 13; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY CD3; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OKT 3; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANEMIA; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DIALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG RESEARCH; DRUG RESPONSE; DYSERYTHROPOIESIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFLAMMATION; KIDNEY FAILURE; LYMPHOCYTE COUNT; MALNUTRITION; MONOCYTE; MORTALITY; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TERATOGENICITY; TREATMENT OUTCOME;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPOETIN ALFA; ERYTHROPOIETIN; HUMANS; INFLAMMATION; INTERFERON TYPE II; INTERLEUKINS; KIDNEY FAILURE, CHRONIC; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RENAL DIALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4544362340     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1060     Document Type: Article

References (10)

1. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906
2. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953-960
3. Street NE, Mossman TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991; 5: 171-177
4. Girndt M, Köhler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Büschenfelde K-H, Fleischer B. Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559-565
5. Girndt M, Sester U, Kaul H, Köhler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998; 9: 1689-1696
6. Memoli B, Marzanon L, Bisesti V, Andrelucci M, Guida B. Hemodialysis-related lymphonuclear release of interleukin-12 in patients with end-stage renal disease. J Am Soc Nephrol 1999; 10: 2171-2176
7. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alfa, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003; 14: 1776-1784
8. Cooper AC, Breen CP, Vyas B, Ochola J, Kemeny DM, Macdougall IC. Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production. Nephrol Dial Transplant 2003; 18: 133-140
9. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004; 15: 1877-1882
10. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-1211